The authors found that CTLA4-Ig modulates peripheral blood-derived CD4pos cell subtypes in RA patients in terms of Th17 CD4pos cells decrease, a trend toward the normalization of Tregs and an effect on IL-6 burden. Here, IL6 is linked to rheumatoid arthritis.